Roche (RHHBY) obtains the European Commission’s (EC) approval for Alecensa (alectinib) monotherapy, as adjuvant treatment following tumor resection for adult patients with anaplastic lymphoma kinase (ALK)- positive non-small cell lung cancer (NSCLC) at high risk of recurrence. Approximately half of all patients with early-stage NSCLC experience disease recurrence following surgery, despite adjuvant chemotherapy. Hence, Alecensa can now address this patient population. Please note that Alecensa is already ap ...